AKT3

Oncogene
RAC-gamma serine/threonine-protein kinase UniProt accession Q9Y243

AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported.

AKT3 is the least studied AKT isoform. It plays an important role in brain development and is crucial for the viability of malignant glioma cells. AKT3 isoform may also be the key molecule in up-regulation and down-regulation of MMP13 via IL13.

Required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis

Source: UniProt

Interacts (via PH domain) with TCL1A; this enhances AKT3 phosphorylation and activation. Interacts with TRAF6. Interacts with KCTD20 (By similarity).

Interacts with BTBD10 (By similarity)

Source: UniProt
Nucleus, Cytoplasm, Membrane — Peripheral membrane protein
Source: UniProt

In adult tissues, it is highly expressed in brain, lung and kidney, but weakly in heart, testis and liver. In fetal tissues, it is highly expressed in heart, liver and brain and not at all in kidney

Source: UniProt

Binding of the PH domain to the phosphatidylinositol 3-kinase alpha (PI(3)K) results in its targeting to the plasma membrane

Source: UniProt
  • Unknown disease
  • Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2 (MPPH2)

    A syndrome characterized by megalencephaly, hydrocephalus, and polymicrogyria; polydactyly may also be seen. There is considerable phenotypic similarity between this disorder and the megalencephaly-capillary malformation syndrome.

Source: UniProt
  • Activation of BAD and translocation to mitochondria
  • PIP3 activates AKT signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the nucleus
  • Negative regulation of the PI3K/AKT network
  • AKT-mediated inactivation of FOXO1A
  • CD28 dependent PI3K/Akt signaling
  • Co-inhibition by CTLA4
  • G beta:gamma signalling through PI3Kgamma
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • RAB GEFs exchange GTP for GDP on RABs
  • RUNX2 regulates genes involved in cell migration
  • Regulation of PTEN stability and activity
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • KEAP1-NFE2L2 pathway
  • SARS-CoV-2 targets host intracellular signalling and regulatory pathways
  • Transcriptional and post-translational regulation of MITF-M expression and activity
Source: Reactome via UniProt

Mutations

Cancer Type Mutation Percentage
Central Nervous System Astrocytoma Grade Iv 0.28%
Lung Adenocarcinoma 1.31%
Lung Small Cell Carcinoma 0.59%
Lung Squamous Cell Carcinoma 1.09%
Oesophagus Adenocarcinoma 1.86%
Oesophagus Squamous Cell Carcinoma 0.35%
Pancreas Ductal Carcinoma 0.98%

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to AKT3, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 5

NCT ID Condition Brief Title Phase Status
NCT03310541 Breast Cancer, Prostate Cancer, Advanced Solid Tumors AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations PHASE1 COMPLETED
NCT02476955 Solid Tumors, Ovarian Cancer, Endometrial Cancer Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole PHASE1 TERMINATED
NCT06425926 Melanoma Stage IV, Solid Tumor Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors PHASE1, PHASE2 RECRUITING
NCT01473095 Solid Tumor, Malignant Lymphoma, Tumor Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma PHASE1 COMPLETED
NCT02761694 Cancer, Solid Tumors Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) PHASE1 TERMINATED